CLDX
Celldex Therapeutics, Inc
stockNASDAQ
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 29.37 | 2026-10-21 | +0.92% | 1.325 |
| 1M | 31.49 | 2026-09-28 | -5.88% | 1.894 |
| 3M | 35.58 | 2026-07-28 | -16.70% | 0.516 |
| 6M | 33.23 | 2026-04-28 | -10.80% | 0.764 |
| 1Y | 27.06 | 2025-10-28 | +9.53% | 1.228 |
| 2Y | 27.97 | 2024-10-28 | +5.97% | — |
| 5Y | 44.58 | 2021-10-28 | -33.51% | 1.253 |
Celldex Therapeutics, Inc (NASDAQ:CLDX) stock price today is $29.64, and today's volume is 899,158. CLDX is down 1.692% today. The 30 day average volume is 1.97M. CLDX market cap is $2.33B with 78.53M shares outstanding.